Trelegy Ellipta
1 known investors
TRELEGY is a once-daily prescription inhaler used long-term to treat COPD (including chronic bronchitis and emphysema) and asthma in adults. It combines an inhaled corticosteroid, an anticholinergic, and a long-acting beta2-adrenergic agonist, and is not intended as a rescue inhaler.
Biotech
Investors · 1
Frequently asked questions
- What does Trelegy Ellipta do?
- TRELEGY is a once-daily prescription inhaler used long-term to treat COPD (including chronic bronchitis and emphysema) and asthma in adults. It combines an inhaled corticosteroid, an anticholinergic, and a long-acting beta2-adrenergic agonist, and is not intended as a rescue inhaler.
- Who are Trelegy Ellipta's investors?
- Trelegy Ellipta's investors include HEALTHCARE ROYALTY PARTNERS.